GLUE insider transactions
Monte Rosa Therapeutics Inc. (GLUE) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for GLUE
- President & CEO Warmuth Markus sold $220,219 worth of shares (9,500 units at $23.18), decreasing direct ownership by 2% to 585,038 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer exercised 4,351 shares at a strike of $3.98 and sold $101,730 worth of shares (4,351 units at $23.38) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $139,849 worth of shares (6,000 units at $23.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Director Behbahani Ali disposed of 1,015,000 shares and acquired 15,000 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip exercised 5,407 shares at a strike of $13.41 and sold $132,472 worth of shares (5,407 units at $24.50) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip exercised 6,000 shares at a strike of $7.56 and sold $137,700 worth of shares (6,000 units at $22.95) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $231,100 worth of shares (10,000 units at $23.11) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip exercised 36,000 shares at a strike of $7.56 and sold $882,203 worth of shares (41,845 units at $21.08) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 59,992 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $60,000 worth of shares (3,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan and exercised 2,175 shares at a strike of $3.98 (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon exercised 3,000 shares at a strike of $6.14 and sold $57,000 worth of shares (3,000 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Behbahani Ali4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Schiff Andrew N4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Manning Anthony M.4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Skvarka Jan4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Siu Christine4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Hughes Eric A4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Blackwell Kimberly4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus sold $106,253 worth of shares (5,466 units at $19.44) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 594,538 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $119,220 worth of shares (6,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer exercised 2,175 shares at a strike of $3.98 and sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $180,100 worth of shares (10,000 units at $18.01) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus sold $103,447 worth of shares (5,467 units at $18.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.90% to 600,004 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Warmuth Markus4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Nickson Philip4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Bowen Matthew4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 3 filed by new insider Bowen Matthew3 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Principal Accounting Officer Dunn Edmund sold $2,496 worth of shares (139 units at $17.96), decreasing direct ownership by 0.61% to 22,554 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus sold $97,974 worth of shares (5,466 units at $17.92), decreasing direct ownership by 0.88% to 613,471 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Principal Accounting Officer Dunn Edmund exercised 25,700 shares at a strike of $13.41 and sold $464,886 worth of shares (25,700 units at $18.09) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip sold $179,161 worth of shares (9,189 units at $19.50), decreasing direct ownership by 12% to 65,837 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus sold $128,373 worth of shares (5,466 units at $23.49), decreasing direct ownership by 0.88% to 618,937 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Business & Legal Officer Nickson Philip was granted 28,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 69% to 60,845 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer was granted 35,000 shares and sold $39,882 worth of shares (2,629 units at $15.17), increasing direct ownership by 108% to 62,371 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Principal Accounting Officer Dunn Edmund sold $15,762 worth of shares (1,039 units at $15.17), decreasing direct ownership by 4% to 22,693 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus was granted 90,000 shares and sold $153,748 worth of shares (10,135 units at $15.17), increasing direct ownership by 15% to 624,403 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip was granted 31,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 59% to 75,026 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon was granted 35,000 shares and sold $47,861 worth of shares (3,155 units at $15.17), increasing direct ownership by 88% to 67,845 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Behbahani Ali4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Hughes Eric A4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Siu Christine4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Skvarka Jan4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Schiff Andrew N4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Manning Anthony M.4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Blackwell Kimberly4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Principal Accounting Officer Dunn Edmund sold $9,174 worth of shares (2,062 units at $4.45), decreasing direct ownership by 8% to 23,732 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Director Leo Chandra P. bought $58,383 worth of shares (10,000 units at $5.84) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Business & Legal Officer Nickson Philip was granted 36,000 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Principal Accounting Officer Dunn Edmund was granted 11,850 shares, increasing direct ownership by 85% to 25,794 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Medical Officer Janku Filip was granted 36,000 shares, increasing direct ownership by 392% to 45,189 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Scientific Officer Townson Sharon was granted 36,000 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- President & CEO Warmuth Markus was granted 128,000 shares, increasing direct ownership by 31% to 544,538 units (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Chief Operating Officer Champoux Jennifer was granted 30,000 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 4 filed by Director Hughes Eric A4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- SEC Form 3 filed by new insider Hughes Eric A3 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Large owner Versant Venture Capital Vi, L.P. sold $1,491,041 worth of shares (157,895 units at $9.44), disposed of 1,435,402 shares and acquired 48,945 shares (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Large owner Versant Venture Capital Vi, L.P. sold $7,395,203 worth of shares (1,132,566 units at $6.53) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
- Large owner Versant Venture Capital Vi, L.P. sold $3,404,791 worth of shares (567,213 units at $6.00) (SEC Form 4)4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)